IP Library › Granted Patent US 12,291,523
Granted Patent B2
US 12,291,523 · App. 18/596,586 · Granted May 6, 2025

LXR modulators with bicyclic core moiety

Inventors: Christian Gege (Ehingen, DE); Olaf Kinzel (Heidelberg, DE); Eva Hambruch (Mannheim, DE); Manfred Birkel (Seeheim-Jugenheim, DE); Claus Kremoser (Heidelberg, DE); Ulrich Deuschle (Speyer, DE)
Assignee: ORSOBIO, INC.
C07D409/14A61P1/16C07D209/18C07D401/04C07D403/04C07D403/10C07D405/04C07D405/10C07D405/14C07D409/04C07D413/04C07D417/04C07D417/14C07D451/02C07D471/04C07D495/04C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,291,523
App. No.
18/596,586
Granted
May 6, 2025
Kind
B2
Abstract

The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXRa and/or LXKJ3) and act preferably as inverse agonists of LXR.

Claims (4)

1. A compound that is

or a pharmaceutically acceptable salt thereof.

2. A compound that is

or a pharmaceutically acceptable salt thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2024
From: GEGE, CHRISTIAN; KINZEL, OLAF; HAMBRUCH, EVA; BIRKEL, MANFRED; KREMOSER, CLAUS; DEUSCHLE, ULRICH
To: PHENEX-FXR GMBH
Reel/Frame 066721/0346 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2024
From: PHENEX-FXR GMBH
To: PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT
Reel/Frame 066721/0355 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2024
From: PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT
To: THE LIVER COMPANY INC.
Reel/Frame 066721/0358 →
CHANGE OF NAME Recorded Mar 11, 2024
From: THE LIVER COMPANY INC.
To: ORSOBIO, INC.
Reel/Frame 066793/0504 →
Priority Claims (1)
EP 18180450 · Jun 28, 2018 · regional
Continuity (3)
Continuation 18166831 · Feb 9, 2023
Division 17255821
Related Publication 20240317726A1 · Sep 26, 2024
References Cited (154)
US 9464044B2 · Ahn et al. · 2016 [cited by applicant]
US 9708316B2 · Fink et al. · 2017 [cited by applicant]
US 11136290B2 · Farand et al. · 2021 [cited by applicant]
US 11618747B2 · Gege et al. · 2023 [cited by applicant]
US 11970484B2 · Gege · 2024 [cited by examiner]
US 20070072911A1 · Avolio et al. · 2007 [cited by applicant]
US 20070293547A1 · Molteni et al. · 2007 [cited by applicant]
US 20100184598A1 · Selles et al. · 2010 [cited by applicant]
US 20110288074A1 · Schann et al. · 2011 [cited by applicant]
US 20150210635A1 · Ahn et al. · 2015 [cited by applicant]
US 20150291563A1 · Park et al. · 2015 [cited by applicant]
US 20170226053A1 · Gauvry et al. · 2017 [cited by applicant]
US 20190359565A1 · Farand et al. · 2019 [cited by applicant]
US 20200397807A1 · Pranesh et al. · 2020 [cited by applicant]
US 20210147398A1 · Gege et al. · 2021 [cited by applicant]
US 20220055985A1 · Farand et al. · 2022 [cited by applicant]
US 20230357214A1 · Gege et al. · 2023 [cited by applicant]
AU 2019272538A1 · 2020 [cited by applicant]
CA 3099051A1 · 2019 [cited by applicant]
CN 1476432A · 2004 [cited by applicant]
CN 1863528A · 2006 [cited by applicant]
CN 1950365A · 2007 [cited by applicant]
CN 101184731A · 2008 [cited by applicant]
CN 101213194A · 2008 [cited by applicant]
CN 105209039A · 2015 [cited by applicant]
CN 108137497A · 2018 [cited by applicant]
CN 110914248A · 2020 [cited by applicant]
EP 0535925A1 · 1993 [cited by applicant]
EP 0535926A1 · 1993 [cited by applicant]
EP 2865664A1 · 2015 [cited by applicant]
JP H06145150A · 1994 [cited by applicant]
JP 2007508286A · 2007 [cited by applicant]
JP 2007523087A · 2007 [cited by applicant]
JP 2010506954A · 2010 [cited by applicant]
JP 2012515759A · 2012 [cited by applicant]
JP 2012529436A · 2012 [cited by applicant]
JP 2015525238A · 2015 [cited by applicant]
TW 200602320A · 2006 [cited by applicant]
TW 200637816A · 2006 [cited by applicant]
TW 200745031A · 2007 [cited by applicant]
TW 202003457A · 2020 [cited by applicant]
WO WO9822452A1 · 1998 [cited by applicant]
WO WO9822457A1 · 1998 [cited by applicant]
WO WO9857931A2 · 1998 [cited by applicant]
WO WO9921851A1 · 1999 [cited by applicant]
WO WO0046195A1 · 2000 [cited by applicant]
WO WO0046197A1 · 2000 [cited by applicant]
WO WO0046199A2 · 2000 [cited by applicant]
WO WO0130343A1 · 2001 [cited by applicant]
WO WO0218335A1 · 2002 [cited by applicant]
WO WO0232863A1 · 2002 [cited by applicant]
WO WO0236562A2 · 2002 [cited by applicant]
WO WO02051837A2 · 2002 [cited by applicant]
WO WO03082802A1 · 2003 [cited by applicant]
WO WO2004000831A1 · 2003 [cited by applicant]
WO WO2005014000A1 · 2005 [cited by applicant]
WO WO2005034941A1 · 2005 [cited by applicant]
WO WO2005085188A2 · 2005 [cited by applicant]
WO WO2006050236A2 · 2006 [cited by applicant]
WO WO2007075555A2 · 2007 [cited by applicant]
WO WO2007134169A2 · 2007 [cited by applicant]
WO WO2008003736A1 · 2008 [cited by applicant]
WO WO2008049047A2 · 2008 [cited by applicant]
WO WO2008116833A1 · 2008 [cited by applicant]
WO WO2008119657A1 · 2008 [cited by applicant]
WO WO2008132434A2 · 2008 [cited by applicant]
WO WO2009032116A1 · 2009 [cited by applicant]
WO WO2009032125A1 · 2009 [cited by applicant]
WO WO2009064848A1 · 2009 [cited by applicant]
WO WO2009064852A1 · 2009 [cited by applicant]
WO WO2010010186A1 · 2010 [cited by applicant]
WO WO2010124793A1 · 2010 [cited by applicant]
WO WO2010144452A1 · 2010 [cited by applicant]
WO WO2013012649A1 · 2013 [cited by applicant]
WO WO2013028999A1 · 2013 [cited by applicant]
WO WO2013111150A1 · 2013 [cited by applicant]
WO WO2014085453A2 · 2014 [cited by applicant]
WO WO2016081599A1 · 2016 [cited by applicant]
WO WO2016106266A1 · 2016 [cited by applicant]
WO WO2016207217A1 · 2016 [cited by applicant]
WO WO2017201313A1 · 2017 [cited by applicant]
WO WO2018188795A1 · 2018 [cited by applicant]
WO WO2019016269A1 · 2019 [cited by applicant]
WO WO2019226490A1 · 2019 [cited by applicant]
WO WO2020002611A1 · 2020 [cited by applicant]
WO WO2024097897A1 · 2024 [cited by applicant]
Abulizi et al. “A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice,” FASEB J. (2017); 31(7):2916-2924. [cited by applicant]
Ahn, Sang Bong, et al., “Expression of Liver X Receptor Correlates with Intrahepatic Inflammation and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease,” Digestive Diseases and Sciences (2014); 59(12):2975-2982. [cited by applicant]
Attie, K. M., et al., “Increased lean mass and muscle volume in healthy post-menopausal women treated with ACE-031 (Soluble activin type IIB receptor), an inhibitor of myostatin and other negative regulators of muscle,”… [cited by applicant]
Aurora Fine Chemicals. https://aurorafinechemicals.com/about.html, downloaded on Jul. 16, 2020 (Year: 2020), 1 page. [cited by applicant]
Aurora Fine Chemicalss. [retrieved online] http://online.aurorafinechemicals.com/StrSearch-new.asp?S2=&R 1=&C 1 =&C2=&C3=ON&C4=ON&R2=V2& T1 =70& T2= 1 00&mol In =&B1 =Search&N DISPLAY=20&ALLFIELDS=K24.833.925, downloade… [cited by applicant]
Bakir, F., et al. “Discovery and Structure-activity Relationship Studies of Indole Derivatives as Liver X Receptor (LXR) Agonists,” Bioorganic & Medicinal Chemistry Letters, (2007); 17(12):3473-3479. [cited by applicant]
Capitta et al. “‘Quick and click’ assembly of functionalised indole rings via metal-promoted cyclative tandem reactions,” RSC Advances (2014); 4(103):59297-59301. [cited by applicant]
Childress, E.S., et al., “Small Molecule Mitochondrial Uncouplers and Their Therapeutic Potential,” Journal of Medicinal Chemistry, Jun. 14, 2018, vol. 61(11), pp. 4641-4655. [cited by applicant]
Collins, Jon L., et al. “Identification of a Nonsteroidal Liver X Receptor Agonist through Parallel Array Synthesis of Tertiary Amines,” Journal of Medicinal Chemistry (2002); 45(10):1963-1966. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2030852-21-0: Abstract, 1 page. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2039648-43-4: Abstract, 1 page. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2177727-62-5: Abstract, 1 page. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2188864-14-2: Abstract, 1 page. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2192710-60-2: Abstract, 1 page. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2196006-39-8: Abstract, 1 page. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2196723-55-2: Abstract, 1 page. [cited by applicant]
Day, Christopher P., and James, Oliver F. W., “Steatohepatitis: A tale of two “Hits”?” Gastroenterology (1998); 114(4):842-845. [cited by applicant]
Estes, Chris, et al., “Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030,” Journal of Hepatology (2018) 69(4):896-904. [cited by applicant]
Estes, Chris, et al., “Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease,” Hepatology (2018); 67(1):123-133. [cited by applicant]
Extended European Search Report mailed Nov. 22, 2018, issued in corresponding Application No. 18180450.1, filed Jun. 28, 2018, 8 pages. [cited by applicant]
Faucher, Anne-Marie, et al., “Discovery of Small-Molecule Inhibitors of the ATPase Activity of Human Papillomavirus E1 Helicase,” Journal of Medicinal Chemistry (2004); 47(1):18-21. [cited by applicant]
Flaveny, Colin A., et al., “Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis,” Cancer Cell (2015); 28(1):42-56. [cited by applicant]
Foster “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. (1984); 5(12):524-527. [cited by applicant]
García-Mediavilla, Maria Victoria, et al. “Liver X receptor a-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication.” Laboratory Investigation 92.8 (… [cited by applicant]
Giesbrecht, Heath E., et al. “Thieme Chemistry Journal Awardees—Where Are They Now? Stereoselective Synthesis of Z-Configured α,β-Unsaturated Macrocyclic Lactones and Diolides by Intramolecular Julia-Kocienski Olefinati… [cited by applicant]
Griffett, Kristine, and Burris, Thomas P., “Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease,” Biochemical and Biophysical Research Communications (2016); 479(3):424-428. [cited by applicant]
Griffett, Kristine, et al. “A Liver-Selective LXR Inverse Agonist That Suppresses Hepatic Steatosis,” ACS Chemical Biology (2013); 8(3):559-567. [cited by applicant]
Griffett, Kristine, et al. “The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis.” Molecular Metabolism (2015); 4(4):353-357. [cited by applicant]
Gronemeyer, Hinrich, et al. “Principles for modulation of the nuclear receptor superfamily,” Nature Reviews Drug Discovery (2004); 3(11):950-964. [cited by applicant]
Guo, T., et al., “Myostatin inhibition prevents diabetes and hyperphagia in a mouse model of lipodystrophy,” Diabetes, Oct. 2012, vol. 61(10), pp. 2414-2423, doi: 10.2337/db11-0915. [cited by applicant]
He, Y.P., et al.; “Palladium-Catalyzed Enantioselective Cacchi Reaction: Asymmetric Synthesis of Axially Chiral 2,3-Disubstituted Indoles,” Angewandte Chemie International Edition (2020); 59(5):2105-2109. [cited by applicant]
Huang, Peng, et al. “Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis,” BioMed Research International (2018); 2018: Article 8071093, 8 pages. [cited by applicant]
International Preliminary Report on Patentability dated Nov. 24, 2020, for PCT/US2019/032925, 9 pages. [cited by applicant]
International Preliminary Report on Patentability for PCT/EP2019/067351 mailed Jan. 7, 2021, 7 pages. [cited by applicant]
International Search Report and Written Opinion dated Jan. 29, 2024, for PCT/US2023/078547, 12 pages. [cited by applicant]
International Search Report and Written Opinion dated Jul. 19, 2019, for PCT/US2019/032925, 13 pages. [cited by applicant]
International Search Report mailed Aug. 12, 2019, issued in corresponding Application No. PCT/EP2019/067351, filed Jun. 28, 2019, 5 pages. [cited by applicant]
Kim, J., et al., “Ruthenium-Catalyzed Direct C-H Amidation of Arenes Including Weakly Coordinating Aromatic Ketones,” Chemistry—A European Journal, (2013); 19(23):7328-7333. [cited by applicant]
Kirchgessner, Todd G., et al., “Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils,” Cell Metabolism (2016); 24(2):223-233. [cited by applicant]
Kremoser, Claus, et al. “Panning for SNURMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators,” Drug Discovery Today (2007); 12(19-20):860-869. [cited by applicant]
Li, X., et al.; “Construction of Atropisomeric 3-Arylindoles via Enantioselective Cacchi Reaction,” Organic Letters. (2021); 23(15):5901-5905. [cited by applicant]
Liberti, Maria V., and Jason W. Locasale. “The Warburg Effect: How Does it Benefit Cancer Cells?” Trends in Biochemical Sciences (2016); 41(3):211-218. [cited by applicant]
Liu, Shuman, and Vaziri, Nosratola D., “Role of PCSK9 and Idol in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome,” Nephrology Dialysis Transplantation (2014); 29(3):5… [cited by applicant]
Papageorgiou, Anna-Pia, et al., “Liver X receptor activation enhances CVB3 viral replication during myocarditis by stimulating lipogenesis,” Cardiovascular Research (2015); 107(1):78-88. [cited by applicant]
Patel, Rucha, et al. “Separating the Anti-Inflammatory and Diabetogenic Effects of Glucocorticoids Through LXRβ Antagonism,” Endocrinology (2017); 158(4):1034-1047. [cited by applicant]
Peet, Daniel J., et al., “Cholesterol and Bile Acid Metabolism are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXRα,” Cell (1998); 9(5):693-704. [cited by applicant]
Qu., C, et al. “Cascade photoredox/gold catalysis: access to multisubstituted indoles via aminoarylation of alkynes,” Chemical Communications, (2016); 52(100):14400-14403. [cited by applicant]
RN 1005134-02-0 and RN 1005178-70-0 (both publicly available in 2008) (Year: 2008), 1 page. [cited by applicant]
RN: 2216852 37 6 to RN: 313373 56 7 all 35 compounds, Database Registry [Online] Retrieved from STN, Apr. 22, 2018, 20 pages. [cited by applicant]
Schultz, Joshua R., et al., “Role of LXRs in control of lipogenesis,” Genes & Development (2000); 14(22):2831-2838. [cited by applicant]
Sci Finder entry for RN 2036868-48-9, downloaded on Jul. 16, 2020 (Year: 2020), 1 page. [cited by applicant]
Sreenivasa, G.M., et al. “Synthesis and Characterization of 2-Benzene Sulphonamido-N(2′-Benzothiazolyl 6′-Fluoro-7′-Substituted) Benzamide and 2-(2-Phenyl-4-Benzylidenyl-5-Oxo-Imidazolin-1-YL) N-(2′-Amino (1′, 3′) Benzo… [cited by applicant]
Steffensen, Knut R. “Are Synthetic Compounds that Silence the Liver-X-Receptor the Next Generation of Anti-cancer Drugs?” Cancer Cell (2015); 28(1):3-4. [cited by applicant]
STN file for RN 2036868-48-9, publicly available since Nov. 24, 2016 (Year: 2016), 1 page. [cited by applicant]
Taiwan Office Action mailed Apr. 6, 2020, issued in corresponding Application No. 108121075 filed Jun. 18, 2019, with English Translation, 12 pages. [cited by applicant]
Tanko L.B. “Does Activin Receptor Blockade by Bimagrumab (BYM338) Pose Detrimental Effects on Bone Healing in a Rat Fibula Osteotomy Model?” Calcified Tissue International, (2016); 99(3):310-321. [cited by applicant]
Tian, M., et al.; “Rh(III)-Catalyzed Asymmetric Synthesis of Axially Chiral Biindolyls by Merging C-H Activation and Nucleophilic Cyclization,” Journal of the American Chemical Society (2019); 141(24):9527-9532. [cited by applicant]
Traversari, Catia, et al. “LXR-dependent and -independent effects of oxysterols on immunity and tumor growth,” European Journal of Immunology (2014); 44(7):1896-1903. [cited by applicant]
Voth, C.N., et al.; “Nickel-Catalyzed Arylative Additions on 2-Alkynyl-N-Arylsulfonylanilides to Construct Functionalized Indoles,” European Journal of Organic Chemistry (2020); 2020(6):744-748. [cited by applicant]
Wang, et al. “Dual gold/photoredox-catalyzed bis-arylative cyclization of chiral homopropargyl sulfonamides with diazonium salts: rapid access to enantioenriched 2,3-dihydropyrroles,” Chemical Communications, (2017); 53… [cited by applicant]
Wang, Yuhui, et al. “Transcriptional regulation of hepatic lipogenesis,” Nature Reviews Molecular Cell Biology (2015); 16(11):678-689. [cited by applicant]
Ward, Patrick S., and Thompson, Craig B., “Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate,” Cancer Cell (2012); 21(3):297-308. [cited by applicant]
Yang, Chendong, et al., “Sterol Intermediates from Cholesterol Biosynthetic Pathway as Liver X Receptor Ligands,” Journal of Biological Chemistry (2006); 281(38):27816-27826. [cited by applicant]
Youn, et al. “Unusual 1,2-Aryl Migration and Depalladation of Alkylpalladium Intermediates Containing a syn-b-Hydrogen Atom,” Chemistry Select, (2016); 1(18):5749-5757. [cited by applicant]
Yu, R., et al. “Palladium-Catalyzed Sequential Vinylic C-H Arylation/Amination of 2-Vinylanilines with Aryl boronic Acids: Access to 2-Arylindoles,” Journal of Organic Chemistry, (2018); 83(1):323-329. [cited by applicant]
Zheng, Fenping, et al., “Regulation of Insulin Resistance and Adiponectin Signaling in Adipose Tissue by Liver X Receptor Activation Highlights a Cross-Talk with PPARγ,” PLoS One (Jun. 2014); 9(6):e101269, 11 pages. [cited by applicant]
Zhou, Xiaoye, et al. “Genetic Deletion of Low Density Lipoprotein Receptor Impairs Sterol-induced Mouse Macrophage ABCA1 Expression: a new SREBP1-dependent mechanism,” Journal of Biological Chemistry (2008); 283(4):2129… [cited by applicant]
Zuercher, William J., et al., “Discovery of Tertiary Sulfonamides as Potent Liver X Receptor Antagonists,” Journal of Medicinal Chemistry (2010); 53(8):3412-3416. [cited by applicant]